RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsApril 11, 2024 - Vertex will acquire Phase 2 company Alpine for $65 per share or approximately $4.9 billion in cash.
“Today’s announcement marks a new chapter for Alpine,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. “It became clear during our discussions with the Vertex team that we share many core values, including a commitment to patients, our employees, and an intense drive for innovation. Povetacicept has demonstrated potential best-in-class attributes in IgA nephropathy and has broad development potential across a number of other autoimmune and inflammatory conditions with significant unmet need.
https://www.biospace.com/article/releases/vertex-enters-into-agreement-to-acquire-alpine-immune-sciences/?s=79
https://www.alpineimmunesciences.com/pipeline/